satsumarx.com
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Join Our Team
  • Areas of Focus
    • Migraine
    • Dihydroergotamine
  • Our Research
    • STS101
    • Publications
    • Clinical Trials
  • Information
    • Press Releases
    • SEC Filings
    • Additional Resources
  • Contact

Long-term safety and tolerability of STS101, a novel investigational dihydroergotamine nasal powder: initial data from the ASCEND study 

« Back
satsumarx.com
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Join Our Team
  • Areas of Focus
    • Migraine
    • Dihydroergotamine
  • Our Research
    • STS101
    • Publications
    • Clinical Trials
  • Information
    • Press Releases
    • SEC Filings
    • Additional Resources
  • Contact

 ©2024 Satsuma Pharmaceuticals, Inc. All Rights Reserved. | Terms of Use | Privacy Policy

  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Join Our Team
  • Areas of Focus
    • Migraine
    • Dihydroergotamine
  • Our Research
    • STS101
    • Publications
    • Clinical Trials
  • Information
    • Press Releases
    • SEC Filings
    • Additional Resources
  • Contact